Business
Ikonisys Finalized a Capital Increase Through the Offsetting of Debt
PARIS, May 02, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces a capital increase of €350k through the offsetting of part of the debt owed to two shareholders, including Cambria Equity Partners LP, and the issue of 233,334 new shares of the Company.
About this update from Ikonisys Sa
[{"type":"text","content":"PARIS, May 02, 2025--(BUSINESS WIRE)--Regulatory News:","length":54,"tagName":"p"},{"type":"text","content":"Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces a capital increase of €350k through the offsetting of part of the debt owed to two shareholders, including Cambria Equity Partners LP, and the issue of 233,334 new shares of the Company.","length":419,"tagName":"p"},{"type":"text","content":"This transaction is part of the Company's strategy to strengthen its net financial position and confirms the vision of the Company's major investors.","length":157,"tagName":"p"},{"type":"text","content":"Legal terms of the Capital Increase","length":35,"tagName":"p"},{"type":"text","content":"The implementation of this capital increase, conducted through the offsetting of debt with cancellation of shareholders' subscription rights, was approved by the Board of Directors of the Issuer at its meeting held on April 22, 2025 (the "Capital Increase").","length":272,"tagName":"p"},{"type":"text","content":"The new shares will be issued under the 17th resolution of the Issuer's shareholders' meeting held on September 30, 2024. The settlement-delivery of the new shares is expected to take place on May 5, 2025.","length":213,"tagName":"p"},{"type":"text","content":"In accordance with applicable regulations, the Capital Increase did not require the approval of a notice (le "prospectus") by the Autorité des marchés financiers (the "AMF").","length":194,"tagName":"p"},{"type":"text","content":"Main terms of the Capital Increase","length":34,"tagName":"p"},{"type":"text","content":"The Issuer has issued a total of 233,334 new ordinary shares, with a par value of €0.5 each, to the investor, pursuant to article L. 225-129, 225-129-2 and 225-138 of the French Commercial Code, in accordance with the 17th resolution passed by its General Meeting on September 30, 2024.","length":286,"tagName":"p"},{"type":"text","content":"The issuance price of the new shares issued under the Capital Increase, equal to €1.50 per share, represents a discount of approximately 0.5% on the Ikonisys share price at the close of April 30, 2025.","l...